PASK and colorectal carcinoma: Altogether, our results point to a ZEB2/pCRAF/pASK molecular signature involved in the determination of a quiescent/slow proliferative state that identifies a subset of cells present in baseline conditions and expanded both upon drug treatment and in aggressive CRC subtypes.